Top Considerations of US Debt Limit -- Equity Research on Endo Pharmaceuticals and Amgen, Inc.
(firmenpresse) - HONG KONG -- (Marketwire) -- 07/29/11 -- Today, released its industry report highlighting Endo Pharmaceuticals (NASDAQ: ENDP) and Amgen, Inc. (NASDAQ: AMGN). Full fundamental and technical analysis is available at .
Top considerations within today's market lies with the current status of the US debt ceiling. Despite the US National Gross Domestic Product beginning to move beyond high-watermark, marking a significant shift away from recessionary pressures; continued momentum relies upon a non-default agreement within congress on or before August 2, 2011. The US Department of Commerce has confirmed growth within first quarter 2011, opening the strong possibility of companies within sub-sectors to experience organic revenue growth in the case of successful agreement.
No matter the outcome, Aug. 2 will mark the opportunity for investors to take advantage of equities with high-margin and specialty products. Fundamental positives in this area are provided by limited exposure to rising commodity costs. Although raw material cost increases will continue to pressure margins, well-positioned companies can leverage organic growth and general consolidation of product lines to sustain bottom-line growth. Market-wise investors are looking to build strong cash positions to take advantage of events in the coming weeks, carefully watching for value within equities boasting established pipelines and excellent growth prospects.
World Street Fundamentals has highlighted Endo Pharmaceuticals as a specialty healthcare solutions company focused on branded products and generics, and devices and services. The Company has a portfolio of branded pharmaceuticals, which includes brand names, such as Lidoderm, Opana ER and Opana, Percocet, Frova, Voltaren Gel, Vantas, Valstar, and Supprelin LA. The entire report on Endo Pharmaceuticals (NASDAQ: ENDP) is available here: .
World Street has featured Amgen, Inc. as an independent biotechnology medicines company. Amgen discovers, develops, manufactures and markets medicines for grievous illnesses. It focuses on human therapeutics and concentrates on medicines based on advances in cellular and molecular biology. The entire report on Amgen, Inc. (NASDAQ: AMGN) is available here: .
About World Street
World Street Fundamentals is an online portal for professionals, investors and new-comers to the markets to find in depth comprehensive research and research tools to help guide you through the ever changing financial markets. Covering the top performers in the hottest sectors and providing clarity to investors around the world.
Contact:
Adam Redford
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 29.07.2011 - 07:00 Uhr
Sprache: Deutsch
News-ID 1025852
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
HONG KONG
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 352 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Top Considerations of US Debt Limit -- Equity Research on Endo Pharmaceuticals and Amgen, Inc.
"
steht unter der journalistisch-redaktionellen Verantwortung von
World Street Fundamentals (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
